Searched for
PFIZER COVID
From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...- In the shadow of COVID, health officials fight panic over Hantavirus outbreakA hantavirus outbreak on a cruise ship has sparked public concern. Health officials are working to communicate clearly, drawing lessons fro...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...
- Pfizer exceeds Q4 earnings estimates as covid product sales outperform expectationsStrong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street's projections...
- Pfizer shares sink after it resets 2024 Covid expectationsRevenue from Pfizer's COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a fur...
- China approves use of Pfizer's COVID drug PaxlovidThe National Medical Products Administration said Paxlovid is approved to treat adults who have mild to moderate COVID-19 and high risk of ...
- Pfizer's COVID product sales to top $50 billion this year, investors want moreAlthough Pfizer raised its forecast for the vaccine, developed with Germany's BioNTech SE, by $1 billion to $32 billion, the drugmaker caut...
- SEC no to clinical trial waiver for Pfizer's Covid pillThe SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, ...
- Booster shot of Pfizer Covid vaccine can cut mortality from Delta variant by 90%: StudyA total of 843,208 participants met the eligibility criteria, of whom 758,118 (90 per cent) received the booster during the 54-day study pe...
- Pfizer Covid vaccine provides partial protection against Omicron: StudyThe Pfizer COVID-19 vaccine provides less immunity against Omicron than from other coronavirus variants, according to a lab study that sugg...
- Overseas indemnity new hurdle in India rollout of Pfizer Covid vaccineIndia is reluctant to provide such overseas indemnity but is in talks for an early resolution to facilitate the supply of the Pfizer-BioNTe...
- Researchers urge delay in administering second dose of Pfizer's Covid-19 vaccine, cite strong dataIn its response, Pfizer said that alternative dosing regimens of its vaccine had not been evaluated yet and the decision to do that resided...
- Single dose of Pfizer COVID-19 vaccine provokes strong immune response: Study"This finding can help countries make informed decisions regarding vaccine policy -- for instance, whether those previously infected should...
- Pfizer withdraws vaccine plea as panel seeks India trial dataThe panel observed that incidents of serious adverse effects such as palsy and anaphylaxis and the causality of the events with the vaccine...
- 90-year-old woman from Northern Ireland becomes first patient in UK to receive Pfizer Covid-19 vaccineMargaret Keenan, from Enniskillen, said she felt "so privileged" to receive the jab at University Hospital, Coventry. Keenan become the fir...
- Pfizer seeks emergency use approval for its COVID vaccine in IndiaThe firm, in its application submitted to the drug regulator, has sought permission to import the vaccine for sale and distribution in the ...
- UK approves Pfizer-BioNTech COVID-19 vaccine, first in the world"The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to ap...
- UK vaccine approval 'historic moment' in Covid-19 battle: Pfizer CEO"Today's Emergency Use Authorisation in the UK marks a historic moment in the fight against Covid-19," said Pfizer CEO Albert Bourla.
- Pfizer says analysis shows 3.8% of Covid vaccine participants experienced fatigueIt said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7 per cent of 6,000 volunteer...
Load More
